flaura final analysis: osimertinib for first-line egfrm nsclc
Published 5 years ago • 2.1K plays • Length 8:44Download video MP4
Download video MP3
Similar videos
-
4:38
new agents for egfr nsclc: osimertinib and beyond
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
6:21
flaura study of osimertinib versus tki for 1st line nsclc
-
2:53
oleclumab plus osimertinib for advanced egfrm nsclc
-
3:34
flaura2: egfrm dynamics in nsclc treated with osimertinib
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
9:36
the flaura trial: practice-changing results for egfr mutation-positive nsclc (bmic-007)
-
2:06
final overall survival (os) data from flaura trial
-
7:00
flaura trial: impact of os data in advanced nsclc
-
5:42
osimertinib and the flaura trial
-
3:06
nice rejection of osimertinib: what does this mean for egfr nsclc in the uk?
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
4:56
active trial update: egfrm nsclc
-
4:51
early returns on flaura trial: osimertinib as first line agent in egfr mut-pos. nsclc? (bmic-002)
-
11:47
osimertinib as first-line treatment for egfr mutation-positive advanced nsclc? (bmic-017)
-
4:22
advanced-stage nsclc: overall survival data from flaura
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
3:22
treatment options: newly diagnosed egfr nsclc